Booking Gains on Keryx and What to Look for Next
Research - Why we're booking gains on Keryx (KERX) and an options strategy for the Sept. 7 PDUFA decision on Zerenex.
Read nowSearch Results for kerx
Finally. An Encouraging Week in Biotech
Research - The sector-tracking iShares NASDAQ biotechnology ETF (IBB) took out some major levels of resistance in the Thursday trading session, catching the attention of traders in the … Continue Reading
Read now
FDA Kicks the Can Down the Road for Keryx’s Lead Drug
Insights - The FDA extended the approval decision date for Zerenex (ferric citrate) by 3 months, to September 7, following revisions to Keryx’s new drug application.
Read nowWhy These “Delivery” Trades Delivered Profits This Month
Recap - The congrats this week went to PropThink contributor Ivan Deryugin for his early December suggestion to buy BDSI ahead of a crucial phase 3 readout. The position … Continue Reading
Read now
Three Updates on Three Names PropThink Suggested for the First Half of This Year
Research - With the JP Morgan Healthcare conference in the rearview, here are updates on a few names that PropThink suggested already this year, all of which … Continue Reading
Premium
What You Didn’t Miss this Week, but You Might Next
Insights - Our entire editorial team was in San Francisco this week for the annual confluence of biotech conferences – JP Morgan Healthcare, Biotech Showcase, and OneMedForum … Continue Reading
Read now
A Glance at PropThink’s Winners and Losers in 2013
Insights - It’s New Year’s Eve. This year flew past – and so did biotech. The NASDAQ Biotechnology Index (NBI) will end the year up 60%, while … Continue Reading
Read now